LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
NCT05645510 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75
Last updated 2026-05-11
Summary
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.
Conditions
- Cancer
- Tyrosine Kinase Mutation
- Breast Cancer
- Melanoma
- Multiple Myeloma
- Chronic Leukemia
- Prostate Cancer
- Ovarian Cancer
- Colorectal Cancer
- Lung Cancer
Sponsors & Collaborators
-
Social Sciences and Humanities Research Council of Canada
collaborator OTHER -
University of Alberta
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-24
- Primary Completion
- 2026-06-09
- Completion
- 2026-06-09
Countries
- Canada
Study Locations
More Related Trials
-
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer
NCT00122265 ·Status: TERMINATED
-
Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation
NCT00122252 ·Status: TERMINATED
-
Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer
NCT02710721 ·Status: COMPLETED ·Phase: NA
-
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
NCT04557501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
NCT00967889 ·Status: UNKNOWN
-
Early Detection of Prostate Cancer
NCT04556916 ·Status: RECRUITING ·Phase: NA
-
Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
NCT00230386 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer
NCT00681694 ·Status: UNKNOWN
-
Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy
NCT00127816 ·Status: COMPLETED ·Phase: NA
-
Stereotactic Radiotherapy for Oligometastatic Prostate Cancer
NCT02563691 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
NCT03237702 ·Status: RECRUITING ·Phase: NA
-
MR-guided Tumour Boost
NCT05364229 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Low Dose Hemi-body Radiation For Recurrent Prostate Cancer
NCT03196778 ·Status: COMPLETED ·Phase: NA
-
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT02594202 ·Status: RECRUITING
-
Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer
NCT05656794 ·Status: RECRUITING ·Phase: PHASE2
-
Novel MRI Assessment of Prostate Cancer VALIDATE-PRO
NCT05017181 ·Status: UNKNOWN
-
A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Localized Prostate Cancer
NCT00489060 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
NCT05896371 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT01961713 ·Status: RECRUITING
-
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
NCT03160794 ·Status: RECRUITING ·Phase: NA
-
Immune Monitoring on Sipuleucel-T
NCT02237170 ·Status: COMPLETED
-
Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development
NCT02106416 ·Status: COMPLETED ·Phase: NA
-
Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI
NCT00242112 ·Status: COMPLETED ·Phase: NA
-
Influence of Prostate Cancer Radiation on Aging
NCT04321187 ·Status: COMPLETED
-
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
NCT00538668 ·Status: COMPLETED ·Phase: PHASE1